• 제목/요약/키워드: breast diseases

검색결과 360건 처리시간 0.026초

폐에 발생한 점막-연관 림프조직(MALT) 림프종 1예 (A case report of the Pulmonary Malignant Lymphoma of the mucosa-associated lymphoid tissue(MALT))

  • 온준상;손형태;김창선;이영실;윤상원;유남수;조동일
    • Tuberculosis and Respiratory Diseases
    • /
    • 제43권6호
    • /
    • pp.1019-1027
    • /
    • 1996
  • 폐의 원발성 림프종은 반응성 림프성 병변과 조직학적으로 감별하기가 어려우나, 반응성 림프증식 증은 polyclonality를 보이는 반면에 악성 림프종은 monoclonality를 보이므로 immunohistochemistry, PCR 분석을 이용하여 감별할 수 있다. 저자 등은 59세 여자 환자에서 개흉폐생검과 lmmunorustochemistry로 진단하고, PCR로 재확인한 악성 B-cell 림프종 1례를 경험 하였기에 문헌고찰과 함께 보고하는 바이다.

  • PDF

쿠싱병에 동반된 폐 노카르디아증 1예 (A Case of Pulmonary Nocardiosis in the Patient with Cushing's Disease)

  • 이소영;오연목;임채만;이상도;고윤석;김우성;김동순;김원동;심태선
    • Tuberculosis and Respiratory Diseases
    • /
    • 제57권1호
    • /
    • pp.61-65
    • /
    • 2004
  • 노카르디아증은 기회감염성질환의 일종이지만 쿠싱병 환자에서는 아주 드물게 보고되고 있다. 저자들은 쿠싱병을 가진 52세 여자환자에서 폐결절로 발현하고, 이후 경피적 폐생검후 농흉 및 유방 농양이 발생한 노카르디아증 1예를 경험하였기에 문헌 고찰과 함께 보고하는 바이다.

전흉벽와 피하조직내 종괴로 발현한 원발성 신장암 1예 (A Case of Renal Cell Carcinoma Presented with Chest Wall Metastasis)

  • 송찬호;최형석;신동혁;양상석;이지연;한윤주;윤구섭;김기출;최신은
    • Tuberculosis and Respiratory Diseases
    • /
    • 제48권1호
    • /
    • pp.84-90
    • /
    • 2000
  • 저자들은 안정시 호흡곤란을 주소로 내원하였고 흉벽에 종괴가 있었던 68세 남자환자에서 조직학적 검사상 전형적인 투명세포형의 원발성 신장암으로 진단된 1 예를 경험하였기에 문헌고찰과 함께 보고하는 바이다.

  • PDF

Gemcitabine에 의한 약물 유발성 간질성 폐렴 1예 (A Case of Drug Induced Interstitial Pneumonitis by Gemcitabine)

  • 이성순;함초롬;진재용;이혜란;김수영;김미영;이현경;이혁표;염호기;최수전
    • Tuberculosis and Respiratory Diseases
    • /
    • 제56권3호
    • /
    • pp.315-320
    • /
    • 2004
  • Gemcitabine은 최근 사용이 증가되고 있는 항암제로서 호흡기 부작용이 흔히 발생하나 대부분 일시적이고 자연 관해된다. 하지만 드물게 gemcitabine에 의한 심각한 폐 독성이 발생할 수 있으며, 이는 조기 진단 및 치료가 중요하다. 저자들은 gemcitabine 치료 후 발생한 중증 약물 유발성 간질성 폐렴 환자에서 스테로이드 치료 후 호전된 증례를 경험하였기에 보고하는 바이다.

거연한간(居延漢簡)과 상한론(傷寒論)의 병증(病症) 비교 연구 (Comparative Study on Diseases and Symptoms between Shanghan-lun and Juyan Wooden Slips)

  • 하기태;정한솔;신상우
    • 동의생리병리학회지
    • /
    • 제25권1호
    • /
    • pp.19-28
    • /
    • 2011
  • More than 30,000 Wooden Slips were excavated in the Juyan region in 1930s and 1970s. These slips recorded military actions of Juyan Frontier Fortress during Han dynasty, which is about BC 100 ~ AD 30. On the slips, there are many disease names and symptoms mentioned. We focused on a certain disease name, namely, Shnaghan(傷寒; injured by cold), which is the main subject of Shangha-lun(傷寒論). Looking closely into these Juan Wooden Slips, we found many articles recording Shanghan, including related diseases and symptoms, such as Shanghan(傷汗; injured by sweat), headache, fever and chills, immobilization of limbs, unacceptance of foods. And there are another Shanghan-related symptoms, such as inflation of upper-abdomen(心腹支滿), pain of upper abdomen(心腹痛), strain of both armpits(兩胠葥急), inflation of chest(胸脇支滿), tightness and fear in the chest(煩滿). Although they have no direct relationship with Shanghan, there are many symptoms, including the external wounds of waist, finger, thigh, back, breast and head, abscess of leg and elbow, sore throat, itching, leucorrhea, powerlessness of hands and legs(手足癃), visceral injury(傷臟), tinnitus, cold, warm and heat. Because the Wooden Slips are very short, with some characters even missing, we can not confirm the detail of the disease and symptoms. In addition, we will report about the herbal medicines and other treatments, which are recorded on the slips, by further research.

Albendazole and Mebendazole as Anti-Parasitic and Anti-Cancer Agents: an Update

  • Chai, Jong-Yil;Jung, Bong-Kwang;Hong, Sung-Jong
    • Parasites, Hosts and Diseases
    • /
    • 제59권3호
    • /
    • pp.189-225
    • /
    • 2021
  • The use of albendazole and mebendazole, i.e., benzimidazole broad-spectrum anthelmintics, in treatment of parasitic infections, as well as cancers, is briefly reviewed. These drugs are known to block the microtubule systems of parasites and mammalian cells leading to inhibition of glucose uptake and transport and finally cell death. Eventually they exhibit ovicidal, larvicidal, and vermicidal effects on parasites, and tumoricidal effects on hosts. Albendazole and mebendazole are most frequently prescribed for treatment of intestinal nematode infections (ascariasis, hookworm infections, trichuriasis, strongyloidiasis, and enterobiasis) and can also be used for intestinal tapeworm infections (taeniases and hymenolepiasis). However, these drugs also exhibit considerable therapeutic effects against tissue nematode/cestode infections (visceral, ocular, neural, and cutaneous larva migrans, anisakiasis, trichinosis, hepatic and intestinal capillariasis, angiostrongyliasis, gnathostomiasis, gongylonemiasis, thelaziasis, dracunculiasis, cerebral and subcutaneous cysticercosis, and echinococcosis). Albendazole is also used for treatment of filarial infections (lymphatic filariasis, onchocerciasis, loiasis, mansonellosis, and dirofilariasis) alone or in combination with other drugs, such as ivermectin or diethylcarbamazine. Albendazole was tried even for treatment of trematode (fascioliasis, clonorchiasis, opisthorchiasis, and intestinal fluke infections) and protozoan infections (giardiasis, vaginal trichomoniasis, cryptosporidiosis, and microsporidiosis). These drugs are generally safe with few side effects; however, when they are used for prolonged time (>14-28 days) or even only 1 time, liver toxicity and other side reactions may occur. In hookworms, Trichuris trichiura, possibly Ascaris lumbricoides, Wuchereria bancrofti, and Giardia sp., there are emerging issues of drug resistance. It is of particular note that albendazole and mebendazole have been repositioned as promising anti-cancer drugs. These drugs have been shown to be active in vitro and in vivo (animals) against liver, lung, ovary, prostate, colorectal, breast, head and neck cancers, and melanoma. Two clinical reports for albendazole and 2 case reports for mebendazole have revealed promising effects of these drugs in human patients having variable types of cancers. However, because of the toxicity of albendazole, for example, neutropenia due to myelosuppression, if high doses are used for a prolonged time, mebendazole is currently more popularly used than albendazole in anti-cancer clinical trials.

전문 질환에 대한 전문병원의 권역내·외 시장점유율 비교 (Market share of specialty hospitals in the region and out of the region)

  • 함명일;김지은;강윤정;이혜원;김선정
    • 한국병원경영학회지
    • /
    • 제28권1호
    • /
    • pp.14-23
    • /
    • 2023
  • Purposes: The Specialty hospital designation policy had launched in 2011 and 110 designated specialty hospitals have been operating nationwide in 2022. This study was to estimate the market share of specialty hospitals for the specific diseases compared to other types of hospitals. Methodology: Data were derived from the National Health Insurance Claim data from 2018 to 2019. Subjects were all the inpatients with MDC(Major Disease Category) that specialty hospitals specialized in. A total of 34,231,387 claims were analyzed to estimate the market share. Findings: 90 specialty hospitals were responsible for 2.4 percent of inpatient care with specific diseases for specialty hospitals. There were regional variations in the market share of the specialty hospitals as the number of specialty hospitals in regions. Specialty hospitals' market shares were relatively high in burn(31.3%), ophthalmology(16.4%), obstetrics and gynecology(7.1%), alcohol(6.0%), joint(3.7%), spine(2.7%). After adjusting the number of inpatients per hospital, hospitals specialized in burn, alcohol, ophthalmology, breast, joint, obstetrics and gynecology, and hand replantation had treated more patients than tertiary hospitals. Practical Implications: Although specialty hospitals' market share was small, some types of specialty hospitals had an impact on the regional market as well as the national level market. To improve patients' accessibility to a specialty hospital, it is necessary to government supports non-specialized hospitals to change into specialty hospitals in certain fields and regions where the number of specialty hospitals is insufficient.

  • PDF

A Hybrid Multi-Level Feature Selection Framework for prediction of Chronic Disease

  • G.S. Raghavendra;Shanthi Mahesh;M.V.P. Chandrasekhara Rao
    • International Journal of Computer Science & Network Security
    • /
    • 제23권12호
    • /
    • pp.101-106
    • /
    • 2023
  • Chronic illnesses are among the most common serious problems affecting human health. Early diagnosis of chronic diseases can assist to avoid or mitigate their consequences, potentially decreasing mortality rates. Using machine learning algorithms to identify risk factors is an exciting strategy. The issue with existing feature selection approaches is that each method provides a distinct set of properties that affect model correctness, and present methods cannot perform well on huge multidimensional datasets. We would like to introduce a novel model that contains a feature selection approach that selects optimal characteristics from big multidimensional data sets to provide reliable predictions of chronic illnesses without sacrificing data uniqueness.[1] To ensure the success of our proposed model, we employed balanced classes by employing hybrid balanced class sampling methods on the original dataset, as well as methods for data pre-processing and data transformation, to provide credible data for the training model. We ran and assessed our model on datasets with binary and multivalued classifications. We have used multiple datasets (Parkinson, arrythmia, breast cancer, kidney, diabetes). Suitable features are selected by using the Hybrid feature model consists of Lassocv, decision tree, random forest, gradient boosting,Adaboost, stochastic gradient descent and done voting of attributes which are common output from these methods.Accuracy of original dataset before applying framework is recorded and evaluated against reduced data set of attributes accuracy. The results are shown separately to provide comparisons. Based on the result analysis, we can conclude that our proposed model produced the highest accuracy on multi valued class datasets than on binary class attributes.[1]

악성 흉막 삼출증의 조직학적 아형에 따른 빈도와 특성 (The Incidences and Characteristics of Malignant Pleural Effusions According to Histologic Types)

  • 임재준;김우진;이재호;유철규;정휘순;한성구;심영수;김영환
    • Tuberculosis and Respiratory Diseases
    • /
    • 제45권3호
    • /
    • pp.565-573
    • /
    • 1998
  • 연구배경: 악성 흉막 삼출증은 폐암에 합병되는 경우가 가장 흔하지만 그 외에 유방암, 난소암, 위암등에서도 호발하며 조직학적 아형에 따라 나누면 선암이 가장 흔하며 편평상피세포암이 악성 흉막 삼출을 일으키는 경우는 매우 드물다고 보고되어왔다. 연자들은 악성 흉막 삼출증의 조직학적 아형에 따른 빈도와 흉수의 특징을 분석하였다. 방 법: 1992년 1월부터 1997년 5월까지 서울대학교 병원에서 흉수의 세포진 검사나 경피적 혹은 흉강경을 이용한 흉막 조직 검사 결과 악성 흉막삼출증로 확인된 84예의 환자를 대상으로 하여 조직 표본과 의무기록을 통해 조직학적 아형을 구분하고 임상적 양상과 생화학적 지표 등을 조사하고 생존기간을 분석하였다. 결 과: 총 84명의 대상 환자 중 남자 52명, 여자 32명으로 남녀 성비는 1.6:1이었고 연령의 중앙값은 56세였다. 환자의 주 증상은 호흡곤란이 42명으로 가장 흔했고 기침과 객담, 흉막성 흉통 등의 순서였으며 평균 생존 기간은 6.4개월이었다. 그 중 혈성 흉수의 빈도는 66%. 림프구 우위성은 39%, 삼출성 흉수는 93%였고 조직학적 아형은 선암 54예(33예가 폐암), 편평상피세포암 10예 (8예가 폐암), 악성림프종 10예, 소세포암 8예 그리고 악성 중피종과 백혈병이 각각 1예였고 각각의 혈성 흉수, 림프구 우위성, 삼출성 흉수의 빈도는 별다른 차이가 없었으며 생화학적 수치의 차이도 관찰되지 않았다. 악성 흉막 삼출을 일으킨 원인 질환은 폐암이 49예로 가장 많았고 그외 원발 부위 불명확 악성 종양 7예, 위암, 유방암이 각각 5예, 담관암이 3예 그리고 난소암, 급성 백혈병, 악성 중피종이 각각 1예 씩 이었고 각각의 혈성 흉수, 림프구 우위성, 삼출성 흉수의 빈도, 생화학적 지표의 차이도 역시 관찰되지 않았다. 결 론: 같은 시기의 서울대학교병원의 폐암의 조직학적 아형의 빈도가 편평상피세포암 47%, 선암 33%, 소세포암 12%, 대세포암 2%인 것과 비교해보면 선암에서 악성 흉악 삼출증이 호발하며 편평 상피 세포암에서는 상대적으로 드물다는 것을 확인할 수 있었고 악성 흉막 삼출증 환자를 조직학적 아형이나 원발 악성 질환에 따라 분류하였을 때 혈성 흉수, 림프구 우위성, 삼출성 흉수의 빈도의 차이는 없었다.

  • PDF

臨證指南醫案에 나타난 피부외과 질환에 대한 문헌고찰 (A Literature Study of Dermatosurgical Diseases in the ImJeungJiNamUiAn)

  • 조재훈;채병윤;김윤범
    • 한방안이비인후피부과학회지
    • /
    • 제15권2호
    • /
    • pp.271-288
    • /
    • 2002
  • Authors investigated the pathogenesis and treatment of dennatosurgical diseases in the ImJeungJiNamUiAn(臨證指南醫案). 1. The symptoms and diseases of dermatosurgery were as follows; 1) BanSaJinRa(반사진라) : eczema, atopic dermatitis, seborrheic dermatitis, psoriasis, lichen planus, pityriasis rosea, hives, dermographism, angioedema, cholinergic urticaria, urticaria pigmentosa, acne, milium, syringoma, keratosis pilaris, discoid lupus erythematosus, hypersensitivity vasculitis, drug eruption, polymorphic light eruption, rheumatic fever, juvenile rheumatoid arthritis(Still's disease), acute febrile neutrophilic dermatosis(Sweet's syndrome), Paget's disease, folliculitis, viral exanthems, molluscum contagiosum, tinea, tinea versicolor, lymphoma, lymphadenitis, lymphangitis, granuloma annulare, cherry angioma 2) ChangYang(瘡瘍) : acute stage eczema, seborrheic dermatitis, stasis ulcer, intertrigo, xerosis, psoriasis, lichen planus, ichthyosis, pityriasis rosea, rosacea, acne, keratosis pilaris, dyshidrosis, dermatitis herpetiformis, herpes gestationis, bullae in diabetics, pemphigus, lupus erythematosus, fixed drug eruption, erythema multiforme, toxic epidermal necrolysis, toxic shock syndrome, staphylococcal scaled skin syndrome, scarlet fever, folliculitis, impetigo, pyoderma gangrenosum, tinea, candidiasis, scabies, herpes simplex, herpes zoster, chicken pox, Kawasaki syndrome, lipoma, goiter, thyroid nodule, thyroiditis, hyperthyroidism, thyroid cancer, benign breast disorder, breast carcinoma, hepatic abscess, appendicitis, hemorrhoid 3) Yeok(疫) : scarlet fever, chicken pox, measles, rubella, exanthem subitum, erythema infectiosum, Epstein-Barr virus infection, cytomegalovirus infection, hand-foot-mouth disease, Kawasaki disease 4) Han(汗) : hyperhidrosis 2. The pathogenesis and treatment of dermatosurgery were as follows; 1) When the pathogenesis of BalSa(발사), BalJin(發疹), BalLa(발라) and HangJong(項腫) are wind-warm(風溫), exogenous cold with endogenous heat(外寒內熱), wind-damp(風濕), the treatment of evaporation(解表) with Menthae Herba(薄荷), Arctii Fructus(牛蒡子), Forsythiae Fructus(連翹) Mori Cortex(桑白皮), Fritillariae Cirrhosae Bulbus(貝母), Armeniaoae Amarum Semen(杏仁), Ephedrae Herba(麻黃), Cinnamomi Ramulus(桂枝), Curcumae Longae Rhizoma(薑黃), etc can be applied. 2) When the pathogenesis of BuYang(부양), ChangI(瘡痍) and ChangJilGaeSeon(瘡疾疥癬) are wind-heat(風熱), blood fever with wind transformation(血熱風動), wind-damp(風濕), the treatment of wind-dispelling(疏風) with Arctii Fructus(牛蒡子), Schizonepetae Herba(荊芥), Ledebouriellae Radix(防風), Dictamni Radicis Cortex(白鮮皮), Bombyx Batrytioatus(白??), etc can be applied. 3) When the pathogenesis of SaHuHaeSu(사후해수), SaJin(사진), BalJin(發疹), EunJin(은진) and BuYang(부양) are wind-heat(風熱), exogenous cold with endogenous heat(外寒內熱), exogenous warm pathogen with endogenous damp-heat(溫邪外感 濕熱內蘊), warm pathogen's penetration(溫邪內陷), insidious heat's penetration of pericardium(伏熱入包絡), the treatment of Ki-cooling(淸氣) with TongSeongHwan(通聖丸), Praeparatum(豆?), Phyllostachys Folium(竹葉), Mori Cortex(桑白皮), Tetrapanacis Medulla(通草), etc can be applied. 4) When the pathogenesis of JeokBan(적반), BalLa(발라), GuChang(久瘡), GyeolHaek(結核), DamHaek(痰核), Yeong(?), YuJu(流注), Breast Diseases(乳房疾患) and DoHan(盜汗) are stagnancy's injury of Ki and blood(鬱傷氣血), gallbladder fire with stomach damp(膽火胃濕), deficiency of Yin in stomach with Kwolum's check (胃陰虛 厥陰乘), heat's penetration of blood collaterals with disharmony of liver and stomach(熱入血絡 肝胃不和), insidious pathogen in Kwolum(邪伏厥陰), the treatment of mediation(和解) with Prunellae Spica(夏枯草), Chrysanthemi Flos(菊花), Mori Folium (桑葉), Bupleuri Radix(柴胡), Coptidis Rhizoma(黃連), Scutellariae Radix(黃芩), Gardeniae Fructus(梔子), Cyperi Rhizoma(香附子), Toosendan Fructus(川?子), Curcumae Radix(鬱金), Moutan Cortex(牧丹皮), Paeoniae Radix Rubra(赤芍藥), Unoariae Ramulus Et Uncus(釣鉤藤), Cinnamorni Ramulus(桂枝), Paeoniae Radix Alba(白芍藥), Polygoni Multiflori Radix (何首烏), Cannabis Fructus (胡麻子), Ostreae Concha(牡蠣), Zizyphi Spinosae Semen(酸棗仁), Pinelliae Rhizoma(半夏), Poria(백복령). etc can be applied. 5) When the pathogenesis of BanJin(반진), BalLa(발라), ChangI(瘡痍), NamgChang(膿瘡). ChangJilGaeSeon(瘡疾疥癬), ChangYang(瘡瘍), SeoYang(署瘍), NongYang(膿瘍) and GweYang(潰瘍) are wind-damp(風濕), summer heat-damp(暑濕), damp-warm(濕溫), downward flow of damp-heat(濕熱下垂), damp-heat with phlegm transformation(濕熱化痰), gallbladder fire with stomach damp(膽火胃濕), overdose of cold herbs(寒凉之樂 過服), the treatment of damp-resolving(化濕) with Pinelliae Rhizoma(半夏), armeniacae Amarum Semen(杏仁), Arecae Pericarpium(大腹皮), Poria(백복령), Coicis Semen(薏苡仁), Talcum(滑石), Glauberitum(寒水石), Dioscoreae Tokoro Rhizoma(??), Alismatis Rhizoma(澤瀉), Phellodendri Cortex(黃柏), Phaseoli Radiati Semen(?豆皮), Bombycis Excrementum(?沙), Bombyx Batryticatus(白??), Stephaniae Tetrandrae Radix(防己), etc can be applied. 6) When the pathogenesis of ChangPo(瘡泡), hepatic abscess(肝癰) and appendicitis(腸癰) are food poisoning(食物中毒), Ki obstruction & blood stasis in the interior(기비혈어재과), damp-heat stagnation with six Bu organs suspension(濕熱結聚 六腑不通), the treatment of purgation(通下) with DaeHwangMokDanPiTang(大黃牧丹皮湯), Manitis Squama(穿山甲), Curcumae Radix(鬱金), Curcumae Longae Rhizoma(薑黃), Tetrapanacis Medulla(通草), etc can be applied. 7) When the pathogenesis of JeokBan(적반), BanJin(반진), EunJin(은진). BuYang(부양), ChangI(瘡痍), ChangPo(瘡泡), GuChang(久瘡), NongYang(膿瘍), GweYang(潰瘍), Jeong(정), Jeol(癤), YeokRyeo(疫?) and YeokRyeolpDan(疫?入?) are wind-heat stagnation(風熱久未解), blood fever in Yangmyong(陽明血熱), blood fever with transformation(血熱風動), heat's penetration of blood collaterals(熱入血絡). fever in blood(血分有熱), insidious heat in triple energizer(三焦伏熱), pathogen's penetration of pericardium(心包受邪), deficiency of Yong(營虛), epidemic pathogen(感受穢濁), the treatment of Yong & blood-cooling(淸營凉血) with SeoGakJiHwangTang(犀角地黃湯), Scrophulariae Radix(玄參), Salviae Miltiorrhizae Radix(丹參), Angelicae Gigantis Radix(當歸), Polygoni Multiflori Radix(何首烏), Cannabis Fructus(胡麻子), Biotae Semen(柏子仁), Liriopis Tuber(麥門冬), Phaseoli Semen(赤豆皮), Forsythiae Fructus(連翹), SaJin(사진), YangDok(瘍毒) and YeokRyeoIpDan(역려입단) are insidious heat's penetration of pericardium(伏熱入包絡), damp-warm's penetration of blood collaterals(濕溫入血絡), epidemic pathogen's penetration of pericardium(심포감수역려), the treatment of resuscitation(開竅) with JiBoDan(至寶丹), UHwangHwan(牛黃丸), Forsythiae Fructus(連翹), Curcumae Radix(鬱金), Tetrapanacis Medulla(通草), Acori Graminei Rhizoma(石菖蒲), etc can be applied. 9) When the pathogenesis of SaHuSinTong(사후신통), SaHuYeolBuJi(사후열부지), ChangI(瘡痍), YangSon(瘍損) and DoHan(盜汗) are deficiency of Yin in Yangmyong stomach(陽明胃陰虛), deficiency of Yin(陰虛), the treatment of Yin-replenishing(滋陰) with MaekMunDongTang(麥門冬湯), GyeongOkGo(瓊玉膏), Schizandrae Fructus(五味子), Adenophorae Radix(沙參), Lycii Radicis Cortex (地骨皮), Polygonati Odorati Rhizoma(玉竹), Dindrobii Herba(石斛), Paeoniae Radix Alba(白芍藥), Ligustri Lucidi Fructus (女貞子), etc can be applied. 10) When the pathogenesis of RuYang(漏瘍) is endogenous wind in Yang collaterals(陽絡內風), the treatment of endogenous wind-calming(息風) with Mume Fructus(烏梅), Paeoniae Radix Alba (白芍藥), etc be applied. 11) When the pathogenesis of GuChang(久瘡), GweYang(潰瘍), RuYang(漏瘍), ChiChang(痔瘡), JaHan(自汗) and OSimHan(五心汗) are consumption of stomach(胃損), consumption of Ki & blood(氣血耗盡), overexertion of heart vitality(勞傷心神), deficiency of Yong(營虛), deficiency of Wi(衛虛), deficiency of Yang(陽虛), the treatment of Yang-restoring & exhaustion-arresting(回陽固脫) with RijungTang(理中湯), jinMuTang(眞武湯), SaengMaekSaGunjaTang(生脈四君子湯), Astragali Radix (황기), Ledebouriellae Radix(防風), Cinnamomi Ramulus(桂枝), Angelicae Gigantis Radix(當歸), Ostreae Concha(牡蠣), Zanthoxyli Fructus(川椒), Cuscutae Semen(兎絲子), etc can be applied.

  • PDF